Affinium Pharmaceuticals announced today that full recruitment has been achieved in its multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin&skin structure infections ("ABSSSI"). This Phase 2 trial is the first human efficacy study conducted with a new class of antibiotics designed to specifically inhibit staphylococcal fatty acid biosynthesis via a new drug target, the fatty acid synthase II (FASII) system. Results expected in late 2012 will represent a significant proof-of-concept milestone for this unique, Staphylococcus-specific antibiotic, AFN-1252.
Fainting, also called vasovagal syncope (by about five neurologists and no one else), is a brief loss of consciousness that occurs when blood flow to the brain drops. Its causes are so numerous that it is basically unknown what causes it - everything from dehydration to medications to pregnancy, heart conditions and age - but these triggers all occur among people who have a strong genetic predisposition, according to new research.
For most of our lives; physicians, hospitals, and insurance companies have used paper medical records. They controlled the flow of data, but allowed patients and others access to their records.
Researchers have developed a new method of repairing bone using a synthetic bone graft substitute material. Combined with gene therapy, they say it can mimic real bone tissue and has potential to regenerate bone in patients who have lost large areas of bone from disease or trauma.
The researchers have developed a scaffold material made from collagen and nano-sized particles of hydroxyapatite which acts as a frame for the body’s own cells and repairs bone in the damaged area using gene therapy. The cells are tricked into overproducing bone producing BMPs (proteins), encouraging regrowth of healthy bone tissue.
A new study shows that supplementation with an encapsulated fruit and vegetable juice concentrate (Juice Plus+® Orchard Blend and Garden Blend) was associated with an increase in serum beta-carotene concentrations, reduced abdominal adipose tissue and improved insulin resistance in overweight boys compared to the placebo group. These study results add to the existing body of research about the role of nutrition in promoting children's health.
Sometimes medicine just makes you want to cheer.
While still in the womb, doctors of Leyna Gonzalez discovered a benign tumor the size of a tennis ball growing on the unborn baby’s mouth.
University of Miami/Jackson Memorial Hospital Fetal Therapy Center fetal surgeon Ruben Quintero and his team came to the rescue. Using an endoscope guided by ultrasound they performed a first of its kind surgery and removed the tumor from the baby's mouth - in the 17th week of pregnancy!
A new study has found that individuals taking cholesterol-lowering statin drugs are more likely than non-users to experience decreased energy, fatigue upon exertion, or both. The researchers suggest that these findings should be taken into account by doctors when weighing risk versus benefit in prescribing statins.
Statins are among the most widely used prescription drugs on the market and therefore increased attention has focused on statins' side effects, particularly their effect on exercise. While some patients have reported fatigue or exercise intolerance when placed on statins, randomized trials had not previously addressed the occurrence of fatigue-with-exertion or impaired energy in patients on statins relative to placebo.
A team of Australian scientists has identified new genes that show identifiable changes in the blood of people with bowel cancer.
The discovery has the potential to underpin a new cost-effective blood test that would signal the early stages of bowel cancer. This test could potentially save thousands of lives by supplementing existing screening programs and encouraging those at risk to have a colonoscopy.
The research presented today is the result of over five years of scientific collaboration between Australian biotechnology company Clinical Genomics, CSIRO and the Flinders Centre for Innovation in Cancer at Flinders University in Adelaide, lead by senior investigator Professor Graeme Young.